Background-Statins substantially reduce cardiovascular mortality and appear to have
Introduction
Statins are an established first line treatment for hypercholesterolemia and the most widely prescribed class of drug in the world, with more than 20 million users among the US population 1 .
Randomized trials provide strong evidence that statins reduces the incidence of major coronary events, ischemic stroke and mortality, even in subjects without established cardiovascular disease 2 3 . Recent studies provide evidence that some of the clinical benefits of statins may be related to mechanisms independent of their lipid lowering effects that could be specific for certain statins 4 . Supporting the concept of pleiotropic actions are the described positive cardiovascular outcomes observed with acute, short-term statin treatment before coronary procedures or early treatment in acute coronary syndromes 5 6 . Also, in a recent randomized trial, atorvastatin (a lipophilic statin) outperformed rosuvastatin (hydrophilic statin) in renoprotective effects in diabetic subjects despite lower lipid concentrations in the latter arm 7 . The so called pleiotropic effects of statins involve plaque stabilization, myocardial remodeling and immunomodulation 8 . The clinical translation of these effects is well documented by highquality studies showing that statins improve endothelial and cardiac function 9 , prevent atrial fibrillation 10 , deep vein thrombosis 11 and microalbuminuria 7 , decrease blood pressure (BP) 12 and reduce inflammation 13 . Interestingly, these statin effects are not consistently observed with low cholesterol diets 14 , nor with other lipid lowering medications such as niacin, ezetimibe, CETP inhibitors or fibrates 11 15 16 . To date the multifactorial mechanisms involved in statin´s antithrombotic, antiinflammatory and cardioprotective effects have not been fully elucidated and the hypothetical pleiotropic effect of statins are still a matter of debate.
In addition to dyslipidemia, there is strong evidence supporting a role for reninangiotensin-aldosterone system (RAAS) dysregulation and mineralocorticoid receptor (MR) procedures or early treatment in acute coronary syndromes 5 6 . Also, in a recent ra a and nd ndom om omiz iz ized ed ed t t tri ri rial atorvastatin (a lipophilic statin) outperformed rosuvastatin (hydrophilic statin) in renoprotective effe ect ct cts s s in in in d d dia ia iabe b b ti i ic c su s bjects despite lower lipid con on once ce centrations in the latte te ter r r arm 7 . The so called p pl plei i iotropic ef ffe e ec ct cts of f f s s sta a ati ti tin n ns s s in in inv vo volv lv lve e e pl pl plaq que s sta a abili iza a ation on on, , od an an and d d my my myo oc ocar ar ardi i i l al al r r re em emodel el elin in ing g m m mmu mu munomodu du dulati t o on o 8 . Th Th The cl lin in i ic ic ical t t tra ra rans ns sla a ation on n o o of th hes se ef ef eff fect ct ts is s s w w we el ell do d d cu c cume e ent nt ted e b b by y y h h hig gh g --quual al alit it ity s stu tudi dies es s s sho ho howi i wing ng ng t t tha ha hat t t st st stat at atin in ins s s im im impr pr prov o ove e e en en endo do doth th thel el elia ia ial l l an an and d d ca ca card rd rdia ia iac c c fu f func nc ncti ti tion on on 9 9 , pr pr prev e even en ent t t at at atri ri rial al al activation in the pathogenesis of atherosclerosis, coronary disease, atrial fibrillation and heart failure. These effects are in addition to the well-known role of aldosterone signaling on salt sensitivity of BP and hypertension. 17, 18 For instance, in patients with coronary disease, aldosterone levels predict ischemic events and long-term mortality 19 . Consistently, lower aldosterone levels predict better cardiovascular health in a non-high risk community study such as the Framingham cohort 20 . Further, several trials have shown that the inhibition of RAASparticularly MR blockade-has remarkable similarities with the described pleiotropic effects of statins, specifically related to improvements in atherosclerotic plaque, cardiovascular remodeling, BP and endothelial dysfunction 21 . Despite these clinical similarities, there is insufficient information related to a potential aldosterone inhibitory effect of statins.
In the present study, our primary aim was to evaluate the hypothesis that chronic statin use is associated with lower aldosterone levels. Further, using ex vivo experiments in adrenal zona glomerulosa (ZG) cells we provide complementary information demonstrating a novel role of statins in modulating aldosterone secretion.
Materials and Methods

Human studies
Study 1: Discovery Cohort
Participants were studied within the HyperPATH Protocol, consisting of individuals with mild to moderate hypertension (HTN) evaluated in response to sodium intake and adrenal secretagogues.
The protocol includes rigorous control of several factors that influence RAAS, incorporating antihypertensive medication washout, body positioning and diurnal variation under strictly controlled diets.
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We excluded in this study participants with known or suspected secondary HTN such as primary hyperaldosteronism, Cushing syndrome or renovascular HTN. Participants with coronary disease, stroke, psychiatric illness, drug abuse and severe HTN were also excluded as previously described 22 . Users of other non-statin medication for dyslipidemia were excluded.
Also, to avoid confounding by indication, we excluded in study 1 all diabetic subjects. Each institutional review board approved the protocol and informed consent was obtained before enrollment.
Chronic statin use was considered if participants were on a statin for at least three months prior to the study interventions. Since, lipophilic statins are taken up by many tissues, including adrenal cells 23 , we determined whether lipophilicity influenced adrenal secretion by classifying subjects in three groups: no statin use, low-moderate lipophilic statin (atorvastatin, fluvastatin, lovastatin) or high lipophilic statin (simvastatin) 23, 24 . Hydrophilic statins were excluded in this categorization because of the small sample size in study 1. To explore a dose-dependent effect, statins users were classified according to their LDL reduction capacity 25 (See Supplemental
Material for expanded methods section ).
Human Protocol
Details of this protocol have been published previously 22 26 27 . For the run in phase, all recruited subjects completed a screening visit. To control for the influence that medications may play in aldosterone secretion, all angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB) or mineralocorticoid receptor antagonists (MRA) were discontinued 1 month and all other anti-hypertensive medications were discontinued at least 2 weeks prior the start of the study. Only if necessary, subjects were placed on amlodipine for BP control due to the neutral effect on aldosterone.
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During the intervention phase, each subject was provided with a caffeine-alcohol-free diet containing 100-mEq/day potassium, 1000 mg/day calcium, and 200-mEq/day sodium. On the sixth day of this high salt (HS) diet, participants were admitted to an inpatient research unit.
Blood samples were obtained at 0800 h to measure aldosterone, cortisol, plasma renin activity (PRA), electrolytes, lipid profile, glucose and insulin using standardized and validated methods as previously described (HS baseline, intervention 1) 22 26 27 . To examine the adrenal response of aldosterone to the physiologic secretagogue, Angiotensin II infusion (AngII, Bachem AG, Switzerland) was then administered (3 ng/kg per min for 60 min, HS stimulation, intervention 2).
After completion of 5-7 days on HS, the same subject was placed on the same diet with reduced sodium to 10 mEq/ day (low sodium (LS) diet 10 mEq/ day) in a crossover intervention (LS baseline, intervention 3), that also increases aldosterone secretion. After 1 week of LS diet we measured adrenal steroids after AngII infusion (LS stimulation, intervention 4).
Sodium balance was confirmed by urinary sodium (HS > 150 mEq/24h and LS < 30 mEq/24h). Also, 24h urinary aldosterone and cortisol were collected as an estimation of adrenal daily production. The protocols were standardized across all study sites (Boston, Salt Lake City, Paris).
Analysis of blood pressure and other hemodynamic measures
BP was examined using systolic arterial pressure in repeated measure analysis. Also, we analyzed the effect of statins on salt sensitivity of BP by comparing the difference between baseline HS and LS measurements. We calculated pulse pressure (PP, systolic BP minus diastolic BP) as a surrogate marker of peripheral vascular compliance on HS and LS diets.
Study 2: Replication cohort
Enrolled subjects were part of a randomized trial evaluating the role of MRA in diabetic da da dail il ily pr pr prod od oduc c ucti ti tion on on. Th Th The e e pr pr prot ot otoc oc ocol ol ols s s we e were re re s s sta ta tand nd ndar ar ardi di dize e zed d d ac ac acro ro ross ss ss a a all ll ll s s stu t tudy d dy s s sit it ites es es ( ( (Bo Bo Bos s sto to ton n n, S S Sal al alt t t La La Lake ke ke C C Cit it ity, cardiovascular disease (ClinicalTrials.gov NCT00865124). We included these participants, prior spironolactone randomization, as they were evaluated using the same protocol regarding sodium and AngII interventions.
Description of this protocol has been published previously 28 . The main differences compared to protocol in Study 1 is that all subjects had well-controlled type 2 diabetes and were on an ACE inhibitor. At the start of the 3-month run-in phase, subjects started enalapril 20 mg/day, other anti-hypertensive medications were tapered off, and amlodipine 5-10 mg/day was added if needed. Simvastatin was started if the subject was not on a statin and LDL was >100 mg/dl at the screening visit. In the context of the run-in-phase of a randomized trial, all subjects were evaluated with the same criteria for starting statin therapy, avoiding a selection bias.
Diabetic medications were adjusted to target HbA1c level 7%.
Study participants received the same controlled HS diet described in Study 1 five days before admission to an inpatient unit. Baseline adrenal steroids measurements (HS baseline, intervention 1), and after AngII infusion were performed (HS stimulation, intervention 2) as described in Study 1. Subjects were categorized as no statin use, hydrophilic (pravastatin and rosuvastatin) or lipophilic statin use (atorvastatin, fluvastatin, lovastatin and simvastatin) 24 .
Statins were again classified according to their LDL reduction capacity, including now rosuvastatin users 25 .
Laboratory analysis
Brigham and Women's Hospital served as the central laboratory for all lab processing and all assays used have been extensively reported previously 22 26 27 . All subjects had PRA, aldosterone and cortisol measured in triplicate in each of the intervention points.
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Animal protocol and in vitro studies
Ex vivo adrenal studies were designed to determine whether statins would acutely modulate aldosterone production. Adrenals were isolated from male Wistar rats maintained on HS (Na=1.6%) for 1 week. ZG cells were isolated from adrenal tissues as previously described by carefully dissecting the capsular (glomerulosa) portion 29 . Thus, the statin concentrations used in our studies were based on those concentrations used in previously published in vitro studies in other tissues 30 31 and on our initial observation that different statin doses had similar effects on aldosterone production, thus we chose and intermediate dose. Of note, this ex-vivo protocol was an exploratory study to help understand the potential mechanism of our human results and was not intended to mimic usual plasma levels of AngII or statins levels achieved in humans.
Aldosterone was measured at baseline and 1 hour after stimulation using RIA kit (SIEMENS, Los Angeles, CA) as described by our group 29 Th Th Thus s us, th th the e e st st stat at atin in in c c con on once ce cent nt ntra ra rati ti tion on ons s s us s used ed ed i i in n n ou o our r r st st stud d udi i ies es es wer er ere e e ba ba base se sed d d on on on t t tho ho hose se se c c con on once ce cent nt ntra ra rati ti tion on ons s s us s used ed ed i i in n n isolated following the same protocol measuring basal and stimulated corticosterone in the presence of ACTH (10 -12 M) 32 . The Animal Care Committee at Harvard approved all of the experimental procedures.
Statistical analyses
Baseline analyses included Student's t test and Chi-square; continuous variables are presented as mean +/-standard deviation (SD) and categorical variables as percentage of the total sample.
Due to the unique characteristic of our protocol where several measurements are available in the same subject in four different intervention settings, we performed a mixed model linear regression analysis, thus allowing adjustment for confounders and addressing the effect of statin within and between subjects. Two models were tested and these covariates (fixed effects) were chosen for their clinical importance and significance in univariate analysis whereas identity was the random effect (See Supplemental Material). In study 2, similar repeated measure analyses were performed (See Supplemental Material). P values 0.05 were considered statistically significant. All human analyses were performed using STATA 13. Animal data were analyzed using one-way ANOVA, followed by Tukey's post hoc analysis, using the GraphPad Prism 6 software.
Results
Study 1: Adrenal secretion in hypertensive subjects by statin use
Characteristics of hypertensive participants
After applying the inclusion-exclusion criteria, a total of 1122 aldosterone measurements were available from the HyperPATH cohort. These measurements represent available repeated analyses from 317 subjects at 4 different intervention points (26% on HS baseline, 18% HS within and between subjects. Two models were tested and these covariates (fixed d d e e eff ff ffec ec ects ts ts) ) ) we we were re re chosen for their clinical importance and significance in univariate analysis whereas identity was he ra ra rand nd ndom om om e e eff f ec c ct t t (S ( ( ee Supplemental Material). I I In n n st s s udy 2, similar repe ea eate t t d measure analyses Subjects on statins were similar to those without statin treatment regarding gender, race, sodium intake, potassium and PRA on HS and LS diet ( Table 1) . Subjects using statins were slightly older and heavier thus age and BMI were included as covariates in the adjusted models.
When compared to participants with no treatment, statin users had significantly lower values of unadjusted baseline aldosterone, AngII-stimulated aldosterone and 24h urinary aldosterone on a HS diet (all p <0.001). While on LS diet the effect of statins resembled the effect seen on a HS diet ( Table 2 , Supplemental Figure) . Aldosterone to renin ratio was not different when analyzed by statin use on both HS and LS diet. Of note, cortisol levels had no significant changes when comparing by statin use groups in all measurements (baseline, stimulated, and 24h urinary collection on both diets ( Table 2) .
Repeated measures analyses in hypertensive patients by statin use
As a formal test of our hypothesis we examined the effect of statin use on aldosterone levels in repeated measures analysis using all four measurements of aldosterone while adjusting for potential confounders. Statins users had lower aldosterone levels in repeated measures analysis, Subjects on statins were similar to those without statin treatment regarding ng g g g gen en ende de der, r, r, r r rac ac ace e e, odium intake, potassium and PRA on HS and LS diet ( Table 1) . Subjects using statins were lig ght ht htly ly ly o o old ld lder er er and d d h h heavier thus age and BMI were re re i i in n ncluded as covariate es es i i in the adjusted models.
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We also confirmed that the aldosterone levels were significantly decreased by statins when categorizing by HS (baseline and AngII stimulated, a decrease of 18% in both models) or LS (baseline and AngII stimulated, a decrease of 35%) with a higher effect on LS (Table 3) .
Consistently, we found a significant interaction for the effect of statin use by dietary sodium type, with greater aldosterone differences while on LS, both at baseline (p=0.02 for interaction) and after AngII stimulation (p< 0.001 for the interaction). In contrast, cortisol levels were not affected by statin use. Further, we observed that available LDL levels or systolic BP did not modify the effect of statins on aldosterone when included in the model as a sensitivity analysis.
No interaction between statin use on aldosterone with age, BMI, gender or race was observed.
Non-invasive hemodynamic measurements by statin use
Use of statins was significantly associated with a decrease in systolic BP in repeated measure analysis (BP at baseline and after AngII on both HS and LS, combined effect of 5.57 mmHg, p=0.001) even when adjusted by confounders, and when analyzed on each diet. Further, statin users had reduced salt sensitivity of BP (systolic HS -systolic LS, -5.85 mmHg, p<0.001, Table 4 ). Also, pulse pressure was significantly decreased in statin users when combining the four intervention measurements ( -2.95 mmHg, p=0.004, Table 4 ).
Effect of type and dose of statin
We observed a significant decrease in aldosterone levels related to higher lipophilicity characteristics (1050 observations, -3.11 ng/mL, p-trend 0.001). In addition, we observed a significant decrease in aldosterone upon adjusted repeated measures analysis, comparing high lipophilic statin users to non statin users ( = -6.26 ng/mL, p 0.001) and low-moderate lipophilic statin to non statin users ( = -3.04 ng/mL, p =0.001) as observed in Figure 1 . Also, high
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Study 2: Adrenal secretion in diabetic subjects on liberal sodium diet by statin use
Characteristics of Type 2 diabetic participants
After the inclusion-exclusion criteria were applied, a total of 143 observations in 79 diabetic subjects were available for analysis. As expected in this population, chronic statin use was highly prevalent (69%). The proportion of subjects on the different statins were similar to those in study 1 with simvastatin being the most commonly used (65%), followed by atorvastatin (14%), rosuvastatin (8%), pravastatin (5%) and lovastatin (3%). Subjects on statins were comparable to those without statin treatment regarding age, gender, race, BMI, sodium intake and years of diabetes (Supplementary Table 1 ).
Adrenal hormones secretion on liberal sodium intake in diabetic patients by statin use
Consistent with the findings in study 1, statin use was associated with lower unadjusted aldosterone levels at baseline and after AngII stimulation on HS diet (Supplementary Table 1) .
As all subjects in study 2 were on an ACEI, these results suggest that statins may act downstream from the angiotensin II receptor (AT1R). Again, cortisol levels were similar (baseline and stimulated) when comparing diabetic subjects with or without statin use (Supplementary Table   1 ). Plasma renin levels and potassium levels were not different by statin use.
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Repeated measures analysis in diabetic patients by statin use
As in study 1, we tested the effect of statin use on aldosterone levels using repeated measurements of aldosterone (baseline aldosterone and AngII-stimulated aldosterone) for each subject on HS diet. Statin use associated with decreased aldosterone levels even when adjusted by confounders in both models 1 and 2 ( Table 5 ). This effect was maintained when including LDL levels and systolic BP in the model as a sensitivity analysis. Consistently, cortisol levels
were not modified by statin use ( Table 5 ). Similar to the results in study 1, lower aldosterone levels were related in a stepwise fashion to higher lipophilicity (adjusted -1.11 ng/mL, p-trend =0.003). Further, aldosterone levels in diabetic subjects were lower in those receiving a lipophilic statin as compared with those not on a statin (adjusted -2.19 ng/mL, p =0.002, Figure 1 ) but not when comparing hydrophilic statin to non user (adjusted -1.63 ng/mL, p =0.15, Figure 1) . We also observed a dose response effect when subjects were classified into the following 3 groups: no statin, low dose statin or moderate-high dose statin, ( -1.15 ng/mL, p for the trend = 0.002). When comparing only the moderate-high dose statin to non-users we observed 30% lower adjusted aldosterone levels (p= 0.002), but again no effect on cortisol.
Ex vivo Studies
To confirm whether the lower aldosterone levels observed in statin users could be explained by a direct effect of statins on adrenal secretion (as opposed to an increased aldosterone metabolism in response to statins), we performed ex vivo studies in rodent adrenal cells. In this system, zona glomerulosa (ZG) aldosterone production is increased in response to various secretagogues, including AngII (which uses the AT1R pathway) and potassium (which acts via an AT1R-independent mechanism). Notably we observed that the acute statin effect on aldosterone secretion was dependent on type of statin. Of note, the lipophilic statins, simvastatin and 
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atorvastatin, reduced both potassium-and AngII-stimulated aldosterone production, whereas the hydrophilic statin pravastatin did not have a significant effect on aldosterone acute secretion (Figure 2 ). In the potassium stimulated aldosterone studies, simvastatin had significantly greater blocking effect than pravastatin and atorvastatin.
In addition, we verified that statins did not acutely affect corticosterone production in zona fasciculata cells. Further, statins did not decrease the precursor of aldosterone (corticosterone) in ZG cells, thus suggesting that statins could be modulating the late pathway of aldosterone steroidogenesis.
Discussion
In these short-term RAAS intervention studies, we demonstrate that chronic statin use is associated with reduced aldosterone levels in both hypertensive and diabetic subjects. This association is evident on both high and low sodium diets, in response to an infusion of the aldosterone secretagogue AngII and when measured in 24h urine samples. The effect on aldosterone was specific, as cortisol levels were not modified in any intervention setting.
Interestingly, both human cohort data suggest that lipophilic statins could be more efficient in blocking aldosterone secretion, results that were confirmed ex vivo.
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inhibitors has been described in patients with hypertension, diabetes and heart failure 33, 34 35 .
Further, atorvastatin and simvastatin in humans, both lipophilic statins, reduced angiotensin II sensitivity and downregulate AT1R 36 . Thus, it has been assumed that this synergistic effect is secondary to an effect mediated directly by angiotensin II. However, previous studies have not considered the possibility that this potential synergism maybe secondary to an effect on aldosterone production.
To the best of our knowledge our study is the first to analyze adrenal secretion of aldosterone and cortisol by statin use in the setting of prolonged washout of medications that affect the RAAS, strictly controlled sodium diet and AngII infusion. However, our results
showing a specific effect on aldosterone secretion but not cortisol, as shown by our human and ex vivo data, are supported by several previous studies. An early report, evaluating whether statins impaired adrenal steroidogenesis, showed that nine months of simvastatin significantly decreased aldosterone but not cortisol levels 37 . Moreover, in an animal intervention study, longterm simvastatin treatment on a high sodium diet significantly reduced plasma aldosterone levels 38 . More recently, Palmer et al observed that starting a statin post-myocardial infarction was associated with a significant decrease in aldosterone levels, though values were not adjusted by sodium intake or medications affecting the RAAS 39 . Of note, torcetrapib, a CETP inhibitor for dyslipidemia, was halted from clinical use because of higher mortality. Treatment with the CETP inhibitor led to increased aldosterone levels and subsequent studies showed that the CETP inhibitor induces aldosterone synthase in adrenal cells. 40 . On the other hand, fenofibrate did not changed aldosterone levels in a similar protocol of high sodium diet intervention 41 . In relation to cortisol, there are numerous well-designed studies, including cortisol levels after ACTH stimulation, that demonstrate that typical statin use does not affect cortisol levels 42 . Intriguingly howing a specific effect on aldosterone secretion but not cortisol, as shown by ou ou ur r r hu hu huma ma man n n an an and d d ex vivo data, are supported by several previous studies. An early report, evaluating whether t t tatin in ns s s im im impa pa pair ir ired a a adr d d enal steroidogenesis, showed d d t t tha ha h t nine months of sim im imvastatin significantly d de decr cr creased aldo d st st ster ron n ne e e bu bu but t t no no not t t c co cort rt rtis is isol ol ol le evel l ls s s 37 37 37 . Mo or r reov v ver er er, in in in a a an n an an anim im imal al al in nterve ve vent nt ntio io ion n n st s ud ud udy, y, y, l l lon on ong g ge erm rm rm s simvast st stat a a in n n tr re r atme me ment o o on n n a a a high gh gh sod od odium m m d d diet sig g gni i ifi fi ica c n n ntly y y r re e educ uc uced e e pl lasm m ma a a aldo o ost st steron on ne e e eve e vels ls ls 38 38 . Mo Mo More re re r r rec ec ecen en entl tl tly, P P Pal al alme me mer r r et t et al l l o o obs bs bser er erve e ved d d th th that at at s s sta ta tart rt rtin in ing g g a a a st st stat at at l l l in in in p p pos os ost t t-my m myoc oc ocar ar ardi di dial al al i i inf nf nfar ar arct ct ctio io ion n n renin levels did not change despite a consistent decrease in aldosterone levels. Even though a moderate decrease in aldosterone could be insufficient to upregulate renin secretion, the specific mechanism(s) for the apparent impaired negative feedback warrant further assessment.
There are several novel and exciting results in our work that support a potential role for statins in modulating aldosterone secretion. First, the results are consistent in different intervention settings within the same subjects as well as in different clinical settings, such as hypertension and diabetes. Also, we found dose-response effect for statin use with lower aldosterone levels at higher doses, providing greater evidence for causality. In relation to the type of statins, our data suggest that lipophilic statins, particularly simvastatin, rather than hydrophilic statins, are associated with lower aldosterone levels. The biological plausibility of this finding is supported by the following: 1) different affinity for adrenal tissue described by type of statin showing that radiolabeled simvastatin has a high adrenal uptake (even higher than liver) compared to pravastatin 23 ; 2) previous preliminary reports showing aldosterone levels were modified by simvastatin 37 but not pravastatin 43 ; 3) our ability to replicate our initial findings in a second cohort; and 4) our demonstration that only certain type of statins acutely reduce aldosterone secretion ex vivo.
In relation to our exploratory ex vivo experiments, we observed in adrenal cells that the type of statin affected acute aldosterone production. Lipophilic statins had a greater effect in blocking aldosterone production than pravastatin, a hydrophilic statin. Further, our finding that potassium-stimulated aldosterone could be blocked acutely by statins (up to a 33% reduction), with simvastatin as the most potent and pravastatin the least potent, suggests that statins act downstream from the AT1R to decrease aldosterone production. Consistent with this concept, we found that statin use was associated with lower aldosterone levels in our replication cohort tatins, are associated with lower aldosterone levels. The biological plausibility of of f t t thi hi his s s fi fi find nd ndin in ing g g is upported by the following: 1) different affinity for adrenal tissue described by type of statin how w win in ing g g th th that at at rad d dio io iola l beled simvastatin has a high h h a a adr d d enal uptake (even hi hi high g g er than liver) c co com mp m ared to pr r rav av ava asta ta at ti tin n n 23 23 23 ; ; ; 2) 2) 2) p p pr re revi vi vio ou ous s s p prel l lim im imi in i ary y r r repo po ort rt rts sh sh show owin i i g g g al al aldo do dos steron on one e e l l lev ev evel e e s s we we were re re mo mo modi di difi f ed by y y si s s mv v mva as a tat t tin n n 37 bu u ut n n not o p p pra r r v v vas st s atin in in 4 4 43 ; 3 3) our r r a a abili li ity y y t t to o re e epl pl plic i a a ate e ou u ur in i i itia a al l l find din ngs in n a e e eco co cond nd nd c c coh oh ohor or ort; t; t; a a and nd nd 4 4 4) ) ) ou o our r r de de demo mo mons ns nstr tr trat at atio io ion n n th th that at at on on only l ly c c cer er erta ta tain in in t t typ p ype e e of of of st st stat at atin in ins s s ac ac acut t utel el ely re re redu d duce ce ce where all individuals were being treated with the same type and dose of ACE inhibition drug.
Although we did not find previous studies examining the effect of statins in adrenal cells, our results are consistent with an in vitro study in human mesangial cells showing that atorvastatin suppressed acute aldosterone production induced by angiotensin II 44 . The specific mechanism for aldosterone inhibition, which is beyond the scope of this initial study, remains to be elucidated, but in rats long-term pitavastatin treatment suppressed the expression of aldosterone synthase in the kidney 45 . Reduced cholesterol availability and/or isoprenylation of signaling proteins have been postulated as potential mechanisms for statins modulating steroidogenesis 46 .
Consistent with the concept that statins affect steroidogenesis, a recent meta-analysis showed that statins could lower testosterone in men and in women with polycystic ovary syndrome 47 .
The mechanisms by which statins affect aldosterone production remain to be elucidated and these studies will need to examine and contrast the acute effects of statins on adrenal steroidogenesis as well as chronic in vivo effects.
We additionally showed that statins were associated with lower BP, as previously reported, but also with less salt sensitivity of BP and pulse pressure. As both sodium reabsorption and arterial stiffness have been related to aldosterone dysregulation, these observations could be, at least in part, secondary to aldosterone secretion modulation by statins 48 . A recent study showed that simvastatin outperformed pravastatin in reducing AngII induced hypertension, which is consistent with our human and ex vivo results 49 .
From a clinical perspective we believe that even a moderate decrease of aldosterone may be relevant. For example, the LURIC study showed that a quartile increase in normal aldosterone levels significantly increased cardiovascular mortality after 7 years of follow up 50 . It could be that a modest decrease in aldosterone secretion may be a new and non-traditional effect of statins hat statins could lower testosterone in men and in women with p polycystic ovary s s syn yn yndr dr drom om ome e e 47 47 47 .
The mechanisms by which statins affect aldosterone production remain to be elucidated and hes se e e st st stud ud udie ie ies s s will ll ll n n need to examine and contrast t t the he he a acute effects of stat tin in ins s s on adrenal t t ter r ro oidogenesis s s as a a w w wel el ell as as as c c ch hro ro roni ni nic c c in in in v v viv ivo ef ef effe e ects.
We a a add d d it t tio o onall l ly show w wed ed ed tha a at t t st t tat t tin i s we we were as assoc c cia a ated d d w w wit it i h h h lo o owe w w r B BP, as as as p p prev v vio o ousl ly e e epo po port rt rted ed ed, bu b but t t al al also so so wit it ith h h le le less ss ss s s sal al alt t t s s sen en ensi si siti ti tivi i vity t ty o o of f f BP BP BP a a and nd nd p p pul l ulse se se p p pre re ress ss ssur r ure e e. A A As s s bo bo both th th s s sod od odiu i ium m m that may partially explain their robust cardioprotective actions not consistently observed with other lipid lowering interventions.
Despite novel findings our study has some limitations. First, statin intervention was not randomized and unmeasured confounding variables associated with statin users cannot be ruled.
Second, the acute dietary interventions and AngII infusions have no long term follow up, despite the fact our protocols are the ideal setting to measure aldosterone since they were designed to control all factors that could modulate adrenal secretion. Future studies should make sure that there is not a compensatory increase in ACTH to maintain cortisol levels. In addition, while initial data suggest that statins may modulate the late pathway of aldosterone synthesis, the specific mechanism for the aldosterone decreasing effect of chronic statin use needs to be fully elucidated. Finally, these results should be validated in prospective randomized studies with controlled RAAS modulators and in different populations where statins are routinely used.
Conclusions
In the present study we demonstrate that chronic statin users have lower aldosterone levels in two studies that evaluate RAAS modulation by sodium diet and AngII. The effect of statins on adrenal secretion appears to be specific for aldosterone and related to the lipophilicity and dose of statin. Future confirmation studies and the assessment of potential mechanisms for this novel finding are warranted.
Acknowledgments:
We gratefully acknowledge the support of the staff of the human research centers in which these intervention studies were performed. We also want to thank the Research Co Co Conc nc nclu l sion n ns s s n n n t t the he he p p pre re rese se sent nt nt s s stu t tudy d dy we e e de de demo mo mons ns nstr tr trat at ate e e th th that at at c c chr hr hron on onic ic ic st st stat at atin in in use se sers rs rs h h hav a ave e e lo lo lowe e wer r r al al aldo do dost st ster er eron on one e e le le leve e vels ls ls i i in n n 40. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology. Table 2 . Unadjusted effects of statin use on aldosterone and cortisol levels on sodium diet and angiotensin II interventions.
Hormonal measurements 317 subjects
Control group on HS 
